Grants and Contributions:
Title:
COVID-19 Response (VI): Nasal Vaccine Development
Agreement Number:
957294
Agreement Value:
$2,906,106.67
Agreement Date:
Sep 24, 2020 - Nov 30, 2021
Description:
Development of a Nasal Vaccine for the prevention of coronavirus disease 2019 due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Kirkland, Quebec, CA H9J 2K6
Reference Number:
172-2020-2021-Q2-957294
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
801344995
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 89 days. The total amended value is 1,598,428.67 dollars.
Amendment Date
Aug 17, 2021
Recipient's Operating Name:
Inspirevax
Recipient's Legal Name:
9298436 Canada Inc.
Federal Riding Name:
Lac-Saint-Louis
Federal Riding Number:
24036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: